Orforglipron
Also known as: LY3502970 · Oral GLP-1 agonist · Orfor
The first truly oral (tablet) GLP-1 receptor agonist that is a small molecule — not a peptide requiring oral protection like semaglutide (Rybelsus). Phase 3 trials showed 14.7% weight loss, close to injectable semaglutide. No needle required — once-daily pill with no food restrictions.
What is Orforglipron? The first truly oral (tablet) GLP-1 receptor agonist that is a small molecule — not a peptide requiring oral protection like semaglutide (Rybelsus). Phase 3 trials showed 14.7% weight loss, close to injectable semaglutide. No needle required — once-daily pill with no food restrictions.
How does Orforglipron work? Unlike oral semaglutide (which still requires fasting and is poorly absorbed), Orforglipron is a small non-peptide molecule that binds the GLP-1 receptor with high affinity regardless of food. It activates the same GLP-1 signaling pathways as injectable GLP-1 agonists but with convenient once-daily oral administration and no formulation restrictions.
Benefits of Orforglipron: Fully oral — no injections required; Phase 3: 14.7% weight loss (comparable to injectable semaglutide); No food restrictions for absorption (unlike Rybelsus); Once-daily pill convenience; Significant HbA1c reduction for type 2 diabetes; Manufacturing cost advantages over peptide injectables
Orforglipron dosage: Phase 3 doses: 12-45mg/day. Starting dose 12mg/day, titrate up. FDA approval expected 2025-2026. Available from some research vendors as capsules.
Research status: Clinical Trials
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/orforglipron
Mechanism of Action
Unlike oral semaglutide (which still requires fasting and is poorly absorbed), Orforglipron is a small non-peptide molecule that binds the GLP-1 receptor with high affinity regardless of food. It activates the same GLP-1 signaling pathways as injectable GLP-1 agonists but with convenient once-daily oral administration and no formulation restrictions.
Benefits
- Fully oral — no injections required
- Phase 3: 14.7% weight loss (comparable to injectable semaglutide)
- No food restrictions for absorption (unlike Rybelsus)
- Once-daily pill convenience
- Significant HbA1c reduction for type 2 diabetes
- Manufacturing cost advantages over peptide injectables
Side Effects & Risks
- Nausea and vomiting (GLP-1 class)
- GI side effects similar to injectable GLP-1s
- Phase 3 trials ongoing — not yet FDA approved
- Small molecule — not technically a peptide
Where to Buy Orforglipron
2 options across 2 vendors · Sorted cheapest first · All include direct product link
From
$249.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Research Protocol
- Dose Range
- 12–36 mg
- Frequency
- Once daily oral
- Cycle
- Ongoing / chronic
- Routes
- oral
- Notes
- Phase 3 doses: 12-45mg/day. Starting dose 12mg/day, titrate up. FDA approval expected 2025-2026. Available from some research vendors as capsules.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
Chemical Properties
- CAS Number
- 2187743-93-3
- Mol. Weight
- C24H26F3N3O3S
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About Orforglipron
What is Orforglipron?▾
The first truly oral (tablet) GLP-1 receptor agonist that is a small molecule — not a peptide requiring oral protection like semaglutide (Rybelsus). Phase 3 trials showed 14.7% weight loss, close to injectable semaglutide. No needle required — once-daily pill with no food restrictions.
What are the benefits of Orforglipron?▾
Fully oral — no injections required
What are the benefits of Orforglipron?▾
Phase 3: 14.7% weight loss (comparable to injectable semaglutide)
What are the side effects of Orforglipron?▾
Nausea and vomiting (GLP-1 class)
What is the recommended dosage for Orforglipron?▾
Phase 3 doses: 12-45mg/day. Starting dose 12mg/day, titrate up. FDA approval expected 2025-2026. Available from some research vendors as capsules.
How long should a Orforglipron cycle last?▾
Ongoing / chronic
More Weight Management Peptides
View all Weight Management peptides →5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
Retatrutide
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD-9604
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
MOTS-C
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.